BVXV:NSD-BiondVax Pharmaceuticals Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.13

Change

-0.13 (-3.99)%

Market Cap

USD 0.04B

Volume

0.55M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-11.73 (-7.68%)

USD60.44B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+2.55 (+1.12%)

USD59.22B 22.32 17.39
REGN Regeneron Pharmaceuticals, Inc

-1.96 (-0.38%)

USD55.06B 18.91 14.53
SGEN Seagen Inc

+7.10 (+4.17%)

USD30.48B 64.32 62.62
BNTX BioNTech SE

-10.23 (-8.23%)

USD29.92B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+0.04 (+0.03%)

USD26.72B 28.34 26.92
RPRX Royalty Pharma plc

+0.18 (+0.42%)

USD26.64B 22.60 9.74
GMAB Genmab A/S

-0.37 (-0.96%)

USD25.29B 26.59 2.61
BGNE BeiGene, Ltd

-9.20 (-3.60%)

USD21.65B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BVXV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -66.31% 6% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.31% 6% F 3% F
Trailing 12 Months  
Capital Gain -46.86% 15% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.86% 15% F 7% F
Trailing 5 Years  
Capital Gain -19.74% 55% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.74% 54% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain 63.15% N/A N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.15% N/A N/A 94% A
Risk Return Profile  
Volatility (Standard Deviation) 132.83% N/A N/A 6% F
Risk Adjusted Return 47.55% N/A N/A 68% D+
Market Capitalization 0.04B 12% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.71 14% F 11% F
Price / Cash Flow Ratio -0.49 12% F 59% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -128.58% 17% F 6% F
Return on Assets -67.84% 7% F 3% F
Debt to Equity Ratio -190.28% 95% A 97% A+
Technical Ratios  
Short Ratio 0.14 96% A 94% A
Short Percent N/A N/A N/A N/A N/A
Beta 2.64 7% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector